Serum sTREM2: A Potential Biomarker for Mild Cognitive Impairment in Patients With Obstructive Sleep Apnea

Abstract

ObjectiveCognitive impairment is a common comorbidity in patients with obstructive sleep apnea (OSA) that leads to poor quality of life and a heavier medical burden. However, the assessment and longitudinal tracking of cognitive impairment in OSA is challenging. This study aimed to examine the alternation and related factors of serum soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in patients with OSA, and to explore whether serum sTREM2 could be a biomarker for mild cognitive impairment in OSA patients.MethodsA total of 94 OSA patients and 13 snoring subjects were enrolled in this cross-sectional study. Demographic information, questionnaires, and polysomnography results were collected. Serum sTREM2 levels were quantified using an enzyme-linked immunosorbent assay. Multivariate linear regression was used to analyze the factors influencing sTREM2, and the receiver operating characteristic curve was used to assess the predictive value of serum sTREM2 for mild cognitive impairment in patients with OSA.ResultsPatients with OSA had higher serum sTREM2 levels than the controls. Multivariate linear regression analysis showed that serum sTREM2 levels in patients with OSA were associated with the Montreal Cognitive Assessment score and oxygen depletion index levels. Additionally, serum sTREM2 levels were higher in OSA patients with mild cognitive impairment (MCI) than in those without. The receiver operating characteristic curve showed that at a cutoff value of >18,437 pg/ml, the sensitivity of serum sTREM2 to predict MCI in OSA was 64.62%, the specificity was 68.97%, and the area under the curve was 0.70 (95% CI: 0.58–0.81).ConclusionSerum sTREM2 levels were elevated in patients with OSA, particularly in those with MCI. It therefore has the potential to be a biomarker for MCI in OSA patients.

Plasma soluble triggering receptor expressed on myeloid cells 2 is associated with depression after acute ischemic stroke

“…In a cross-sectional study of 94 patients with obstructive sleep apnea, serum sTREM2 levels were higher in patients with mild cognitive impairment than in those without 33 . Recently, in a previous population-based study, our team found that the risk of post-stroke cognitive impairment increased significantly with the increase of plasma sTREM2 levels among patients with acute ischemic stroke 11 .…”

“…The ectodomain of TREM2 is processed by a disintegrin and metalloprotease, resulting in the release of a soluble form of TREM2, which can be detected in peripheral blood and CSF 31 . sTREM2 has been shown to be associated with the development and progression of neurological diseases, such as Alzheimer's disease, obstructive sleep apnea and sepsis related encephalopathy 13,32,33 .…”

Decoding sTREM2: its impact on Alzheimer’s disease – a comprehensive review of mechanisms and implications

“…The initiating factor of AD-be it protein deposition or disturbed homeostasis-remains uncertain, though the involvement of the innate immune system is clear (Castro-Gomez and Heneka, 2024). Elevated serum levels of sTREM2 may also serve as a promising biomarker for identifying mild cognitive impairment in patients with obstructive sleep apnea, correlating with lower cognitive performance as assessed by the Montreal Cognitive Assessment (Jiahuan et al, 2022). These findings advocate for sTREM2's role in mediating microglial-associated inflammatory responses and suggest its potential as a protective agent in AD.…”

Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects

“…S100B is another astrocytic protein which has been used as a biomarker for neurodegeneration [281]. sTREM2 is the soluble form of TREM2, which is expressed in the CNS mainly on microglia [282] and is a biomarker for microglial activation [283]. YKL-40 is an astrocyte-derived biomarker involved in inflammation, proliferation, and angiogenesis [284].…”